AIMS: To test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo. DESIGN: Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of weekly 30-minute substance abuse counseling. SETTING: The trial was conducted from January 2009 to March 2012 at the San Francisco Department of Public Health. PARTICIPANTS: Ninety actively using, methamphetamine-dependent, sexually active adults were recruited from community venues. MEASUREMENTS: The primary outcome was regression estimated reductions in weekly methamphetamine-positive urines. Secondary outcomes were study medication adherence [by self-report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine. FINDINGS:Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty-three per cent of follow-up visits and final visits were completed. By intent-to-treat, participants assigned to aripiprazole had similar reductions in methamphetamine-positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66-1.19, P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self-report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self-report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05). CONCLUSION: Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
RCT Entities:
AIMS: To test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo. DESIGN:Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of weekly 30-minute substance abuse counseling. SETTING: The trial was conducted from January 2009 to March 2012 at the San Francisco Department of Public Health. PARTICIPANTS: Ninety actively using, methamphetamine-dependent, sexually active adults were recruited from community venues. MEASUREMENTS: The primary outcome was regression estimated reductions in weekly methamphetamine-positive urines. Secondary outcomes were study medication adherence [by self-report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine. FINDINGS:Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty-three per cent of follow-up visits and final visits were completed. By intent-to-treat, participants assigned to aripiprazole had similar reductions in methamphetamine-positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66-1.19, P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self-report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self-report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05). CONCLUSION: Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Thomas P Beresford; Lori Clapp; Brandon Martin; John L Wiberg; Julie Alfers; Henry F Beresford Journal: J Clin Psychopharmacol Date: 2005-08 Impact factor: 3.153
Authors: D S Metzger; B Koblin; C Turner; H Navaline; F Valenti; S Holte; M Gross; A Sheon; H Miller; P Cooley; G R Seage Journal: Am J Epidemiol Date: 2000-07-15 Impact factor: 4.897
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Keith A Hermanstyne; Glenn-Milo Santos; Eric Vittinghoff; Deirdre Santos; Grant Colfax; Phillip Coffin Journal: Drug Alcohol Depend Date: 2014-08-05 Impact factor: 4.492
Authors: Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki Journal: Addiction Date: 2017-08-29 Impact factor: 6.526
Authors: Adam W Carrico; Walter Gόmez; Jennifer Jain; Steven Shoptaw; Michael V Discepola; David Olem; Justin Lagana-Jackson; Rick Andrews; Torsten B Neilands; Samantha E Dilworth; Jennifer L Evans; William J Woods; Judith T Moskowitz Journal: Drug Alcohol Depend Date: 2018-09-05 Impact factor: 4.492